查看“CDK4/6 抑制剂”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[CDK4/6 抑制剂]]</strong>（<strong>[[CDK4/6 Inhibitors]]</strong>）是一类通过特异性抑制 <strong>[[细胞周期蛋白依赖性激酶]]</strong> 4 和 6（CDK4/6）活性来阻断细胞周期的口服靶向药物。该类药物能有效阻止细胞从 <strong>[[G1 期]]</strong> 向 <strong>[[S 期]]</strong> 转化，从而抑制肿瘤细胞的增殖。目前，CDK4/6 抑制剂（如 <strong>[[哌柏西利]]</strong>、<strong>[[阿贝西利]]</strong> 和 <strong>[[瑞波西利]]</strong>）已成为 <strong>[[HR+/HER2- 晚期乳腺癌]]</strong> 的一线标准治疗方案。通过与内分泌药物联合使用，该类抑制剂能显著延长患者的 <strong>[[无进展生存期]]</strong>（PFS），并有效克服或延迟内分泌耐药的发生。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">CDK4/6 抑制剂</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">Cell Cycle Pathway Blockers · 点击展开详情</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px;">[[CDK4/6]] [[Pathway]] Icon</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶向药物类别</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">核心靶点</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[CDK4]] / [[CDK6]]</strong></td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要成员</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">哌柏西利, 阿贝西利, 瑞波西利</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">UniProt ID</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">P11802 (CDK4) / Q00534 (CDK6)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">适应症</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">HR+/HER2- 晚期乳腺癌</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">常见副作用</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">中性粒细胞减少, 腹泻</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569;">药效标志物</th>
                    <td style="padding: 10px 12px;">[[Rb 蛋白]] 磷酸化抑制</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断细胞周期 G1/S 转换</h2>
    <p style="margin: 15px 0; text-align: justify;">
        CDK4/6 抑制剂通过精准干预细胞周期调控网络，恢复对肿瘤细胞失控增殖的限制：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>抑制 Rb 磷酸化：</strong> 在正常细胞周期中，CDK4/6 与 <strong>[[Cyclin D]]</strong> 结合形成复合体，使 <strong>[[视网膜母细胞瘤蛋白]]</strong>（Rb）磷酸化。磷酸化的 Rb 释放转录因子 <strong>[[E2F]]</strong>，从而启动进入 S 期所需的基因转录。CDK4/6 抑制剂通过阻止这一磷酸化过程，使 Rb 保持在非磷酸化激活状态，紧锁 E2F。</li>
        <li style="margin-bottom: 12px;"><strong>诱导细胞衰老：</strong> 长期的周期阻断可诱导肿瘤细胞进入 <strong>[[细胞衰老]]</strong> 状态而非立即凋亡，这种“睡眠”状态能显著延缓肿瘤进展。</li>
        <li style="margin-bottom: 12px;"><strong>协同免疫调节：</strong> 最新研究表明，CDK4/6 抑制剂能通过增加 <strong>[[抗原呈递]]</strong> 和抑制 <strong>[[Treg 细胞]]</strong> 活性，增强机体对肿瘤的免疫监视作用。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床矩阵：主流 CDK4/6 抑制剂对比</h2>
    <div style="overflow-x: auto; margin: 30px auto;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 22%;">药物名称 (通用名)</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">靶点亲和力</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">给药方式</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;">特征性副作用</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[哌柏西利]] (Palbociclib)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">CDK4 ≈ CDK6</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">21天服药/7天停药</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>中性粒细胞减少</strong> (骨髓抑制)。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[阿贝西利]] (Abemaciclib)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">CDK4 > CDK6 (更强)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">每日两次，连续服用</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>腹泻</strong>、静脉血栓风险。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[瑞波西利]] (Ribociclib)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">CDK4 > CDK6</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">21天服药/7天停药</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>QT 间期延长</strong> (心脏监测)。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：内分泌联合与耐药管理</h2>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>一线首选方案：</strong> 临床共识（如 <strong>[[NCCN 指南]]</strong>）推荐 CDK4/6 抑制剂联合 <strong>[[芳香化酶抑制剂]]</strong>（如来曲唑）作为晚期 HR+ 乳腺癌的一线治疗。对于经内分泌治疗后进展的患者，可联合 <strong>[[氟维司群]]</strong>。</li>
        <li style="margin-bottom: 12px;"><strong>耐药后的选择：</strong> 约 20% - 30% 的患者会出现获得性耐药，常见机制包括 <strong>[[CCNE1]]</strong> 扩增或 <strong>[[RB1]]</strong> 基因缺失。耐药后可考虑转换 <strong>[[PI3K 抑制剂]]</strong>（如阿培利司）或 <strong>[[ADC 药物]]</strong>。</li>
        <li style="margin-bottom: 12px;"><strong>辅助治疗前移：</strong> <strong>[[MonarchE]]</strong> 等研究证明，阿贝西利在具有高复发风险的早期乳腺癌患者中同样具有显著的强化辅助治疗价值。</li>
    </ul>

    <div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 10px; padding: 25px; background-color: #ffffff;">
        <h3 style="margin-top: 0; color: #0f172a; font-size: 1.15em; margin-bottom: 20px; border-bottom: 2px solid #3b82f6; display: inline-block; padding-bottom: 5px;">关键相关概念</h3>
        <div style="display: flex; flex-direction: column; gap: 12px; font-size: 0.95em;">
            <div style="color: #334155;"><strong style="color: #1e40af;">[[HR+/HER2- 乳腺癌]]</strong>：CDK4/6 抑制剂的主要获批适应症，占乳腺癌总数的 70% 左右。</div>
            <div style="color: #334155;"><strong style="color: #1e40af;">[[视网膜母细胞瘤蛋白]] (Rb)</strong>：CDK4/6 抑制剂发挥作用的必需“关卡”蛋白。</div>
            <div style="color: #334155;"><strong style="color: #1e40af;">[[骨髓抑制]]</strong>：哌柏西利和瑞波西利的主要限制性毒性，需监测全血细胞计数。</div>
            <div style="color: #334155;"><strong style="color: #1e40af;">[[达尔西利]]</strong> (Dalpiciclib)：中国自主研发的国产 CDK4/6 抑制剂，已获批上市。</div>
        </div>
    </div>

    <div style="font-size: 0.9em; line-height: 1.7; color: #1e293b; margin-top: 50px; border-top: 2.5px solid #0f172a; padding-top: 25px; text-align: left;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Finn RS, et al. (2016).</strong> <em>Palbociclib and Letrozole in Advanced Breast Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong> (<strong>[[NEJM]]</strong>). 2016;375(20):1925-1936.<br>
            <span style="color: #475569;">[学术点评]：PALOMA-2 试验奠定了 CDK4/6 抑制剂在晚期一线治疗中的统治地位。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Hortobagyi GN, et al. (2016).</strong> <em>Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.</em> <strong>[[NEJM]]</strong>.<br>
            <span style="color: #475569;">[学术点评]：[Academic Review] 该研究展示了瑞波西利在改善绝经后患者 PFS 方面的显著优势。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Sledge GW, et al. (2017).</strong> <em>MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer.</em> <strong>[[Journal of Clinical Oncology]]</strong> (<strong>[[JCO]]</strong>).<br>
            <span style="color: #475569;">[学术点评]：揭示了阿贝西利在克服内分泌耐药中的临床潜力。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: left; border-bottom: 1px solid #dbeafe;">
            CDK4/6 抑制剂 · 知识图谱导航
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">核心药物</td>
                <td style="padding: 10px 15px; color: #334155; text-align: left;">[[哌柏西利]] • [[阿贝西利]] • [[瑞波西利]] • [[达尔西利]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">信号通路</td>
                <td style="padding: 10px 15px; color: #334155; text-align: left;">[[Cyclin D-CDK4/6-Rb 通路]] • [[ER 信号通路]] • [[PI3K 通路]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">临床试验</td>
                <td style="padding: 10px 15px; color: #334155; text-align: left;">[[PALOMA 试验]] • [[MONALEESA 试验]] • [[MONARCH 试验]]</td>
            </tr>
        </table>
    </div>

</div>